Real‐World Practice Patterns in Diagnosis and First‐Line Treatment in Metastatic Breast Cancer
The Breast Journal · 2026
DOI: 10.1155/tbj/4333748 ↗Kurz gefasst
Fachartikel in der Zeitschrift The Breast Journal, 2026. Verfasst von Poorni M Manohar und 12 weiteren Autor:innen. Beteiligte Einrichtung: Department of Internal Medicine, Rush University Medical Center, Chicago, Illinois, USA, rush.edu. Hauptthemen laut MEDLINE: Breast Neoplasms, Practice Patterns, Physicians'. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 44 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NCI NIH HHS, NIH HHS, American Society of Clinical Oncology.
Abstract (Originalsprache)
Intro Divergence from national guidelines and variations in practice patterns impact care and outcomes in patients with metastatic breast cancer (MBC). We sought to assess the quality of care in the diagnosis and treatment of real‐world patients with MBC in Washington State.
Methods
Data were retrospectively analyzed using a linked cancer registry and insurance claims platform for patients with recurrent or de novo MBC diagnosed between 2008 and 2019.
Results
We identified 1101 patients with MBC (median age: 66), 715 recurrent and 386 de novo. Most patients were White (89%), all were insured (Commercial [47%], Medicaid [4%], Medicare [35%], or multiple [13%]), and 15% lived in areas of high deprivation (Area Deprivation Index [ADI]: 8–10). Of the patients with recurrent MBC, less than half received a biopsy (49.5%) or biomarker reassessment (48.7%) to confirm the diagnosis of MBC. Patients treated at high‐ and medium‐volume centers had higher rates of biopsy than low‐volume clinics (51.9%, 54.3%, and 40.7%, respectively, p = 0.03). ET alone was more common in patients who did not undergo biopsy (62.3% vs. 37.7%, p < 0.001) or biomarker reassessment (62.7% vs. 37.3%, p < 0.001). Among the 677 patients with estrogen receptor (ER)+/HER2− MBC (de novo and recurrent), most received ET alone (69%), followed by CT (22%) and CDKi + ET (9%). Importantly, 40% of patients were treated before CDK4/6i approval. Most patients who received CDKi + ET were < 65 years old (65.2%, p < 0.02). Patients with commercial insurance were more likely to receive CDKi + ET compared to those with Medicare/Medicaid. (60.9% vs. 26.1%, p = 0.10).
Conclusion
Our findings highlight key gaps in MBC management and serve as a launch point for patient‐centered and quality‐promoting initiatives.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Internal Medicine, Rush University Medical Center, Chicago, Illinois, USA, rush.edu.
- Department of Internal Medicine, University of Washington/Fred Hutchinson Cancer Research Center, Seattle, Washington, USA.
- Department of Internal Medicine, Fred Hutchinson Cancer Research Center, Seattle, Washington, USA, fredhutch.org.
- Pfizer Inc., New York, New York, USA, pfizer.com.
- CHOICE Institute, University of Washington, Seattle, Washington, USA, washington.edu.
ORCID-Profile: Poorni M Manohar, Jennifer M Specht, Josh A Roth
Förderung
- NCI NIH HHS
- NIH HHS
- American Society of Clinical Oncology
- Pfizer
- National Institutes of Health
Zitieren
APA
Manohar, P. M., Shankaran, V., Davidson, N. E., Hunter, N., Gwin, W. R., Yung, R. L., Specht, J. M., Federenko, C., Qin, S., Wu, Q. V., Voustinas, J. M., Roth, J. A., & Linden, H. M. (2026). Real‐World Practice Patterns in Diagnosis and First‐Line Treatment in Metastatic Breast Cancer. The Breast Journal. https://doi.org/10.1155/tbj/4333748
Vancouver
Manohar PM, Shankaran V, Davidson NE, Hunter N, Gwin WR, Yung RL, et al. Real‐World Practice Patterns in Diagnosis and First‐Line Treatment in Metastatic Breast Cancer. The Breast Journal. 2026. doi:10.1155/tbj/4333748
BibTeX
@article{Manohar2026,
author = {Manohar, Poorni M and Shankaran, Veena and Davidson, Nancy E and Hunter, Natasha and Gwin, William R and Yung, Rachel L and Specht, Jennifer M and Federenko, Catherine and Qin, Sun and Wu, Qian Vicky and Voustinas, Jenna M and Roth, Josh A and Linden, Hannah M},
title = {Real‐World Practice Patterns in Diagnosis and First‐Line Treatment in Metastatic Breast Cancer},
journal = {The Breast Journal},
year = {2026},
doi = {10.1155/tbj/4333748}
}
EUVIMED